GOGyeon Oh

Gyeon Oh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gyeon Oh has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Patterns and Characteristics of Gabapentin Use Among Medicare Beneficiaries

    by Gyeon Oh, Daniela C. Moga, Patricia R. Freeman, Erin L. Abner

    Background Gabapentin is increasingly prescribed to older adults, yet prescribing patterns and characteristics of gabapentin initiators remain unclear. Methods We conducted a retrospective cohort study of gabapentin initiators using a random sample of age-eligible fee-for-service Medicare beneficiaries (2012–2021) enrolled in Parts A, B, and D. Gabapentin initiators were identified from pharmacy claims. We required 180 days of continuous enrollment (washout period) prior to initiation (index date) for inclusion. We analyzed demographics, healthcare utilization within 3 months of initiation, chronic conditions, medication history during washout period, and patterns of gabapentin use. Subgroup analyses compared initiators by duration of continuous gabapentin use (≤ 90 days, 91–180 days, and > 180 days). Results The prevalence of gabapentin prescriptions increased over time, from 6.7% (2013) to 10.2% (2021). Among 247,612 gabapentin initiators (mean age 76.1 years, 61.5% female, 89.2% white), chronic pain (32.6%) was the most commonly documented condition, while epilepsy and postherpetic neuralgia, the approved indications for gabapentin, were documented in fewer than 0.5% of initiators. Among initiators, 38.9% had prior opioid use, and 13.2% were co-prescribed gabapentin and opioids at initiation. About 30% had a history of antidepressant use, predominantly selective serotonin reuptake inhibitors (17.2%). Subgroup analyses showed similar demographics and prescription patterns across subgroups. However, gabapentin initiators with > 180 days continuous use had more neuropathic pain and chronic condition diagnoses documented, fewer opioid co-prescriptions at index, and lower hospitalization rates. Conclusions Gabapentin was frequently prescribed, apparently off-label, in older adults with a high burden of chronic pain and comorbidities; initiators often had co-prescriptions of gabapentin with opioids. Future research is needed to investigate factors associated with extended gabapentin use (> 180 days) and its appropriateness in this population.

  • Open Access

    Gabapentin initiation and neurocognitive changes in older adults with cognitive impairment

    by Gyeon Oh, Daniela C Moga, David W. Fardo, Jordan P. Harp, Erin L. Abner

    Background: Gabapentin has been increasingly prescribed to older adults for off‐label indications, and accumulating evidence suggests potential for gabapentin misuse and related adverse events. However, the relation between gabapentin initiation and longer‐term neurocognitive changes is not well understood.Method: A retrospective cohort study was conducted using the National Alzheimer’s Coordinating Center Uniform Data Set (2005‐March 2023). Participants with cognitive impairment at the visit of gabapentin initiation (i.e., index visit) were included. Using the incidence density sampling method, up to 9 non‐users were randomly selected for each initiator. Cognitive decline over one year was defined as any increase in Clinical Dementia Rating global score (CDR®GLOB) or a 1‐point increase in CDR® sum of boxes (CDR®SB). Functional status decline over one year was defined as at least a 3‐point increase in the Functional Activities Questionnaire (FAQ) sum or a 0.3‐point increase of mean of FAQ. Motoric decline over one year was defined as new clinician reports of gait disorder, falls, and slowness. To mitigate confounding and selection bias, joint stabilized inverse probability of treatment weights and censoring weights were used. Generalized estimating equations with an exchangeable working correlation structure were used to fit logistic regression models and account for the weighting, The confounders were selected using directed acyclic graphs. All analyses were conducted comparing index to index+1 and index+2 visits.Result: For the study of cognitive and functional status decline, we included 505 initiators (mean age [SD]: 78.8 [7.4]; male = 45%) and 4,545 non‐users (79.2 [7.6]; 50.1%). For the study of motor decline, we included 353 initiators (78.3 [7.2]; 42.8%) and 3,177 non‐users (78.5 [7.4]; 48.1%). Gabapentin initiation was not statistically associated with decline on CDR®GLOB, CDR®SB, FAQ sum, or mean FAQ at the index+1 or index+2 visits. However, gabapentin initiation was significantly associated with increased odds of new falls at the index+2 visit (odds ratio [95% confidence interval]: 2.1 [1.1, 3.9]) (Figure 1).Conclusion: Over 1 or 2 years of follow‐up, gabapentin initiation was not associated with decline in cognitive or functional status but was associated with increased odds of falling among research participants with cognitive impairment.


  • The Association of Gabapentin Initiation with Cognitive and Behavioral Changes in Older Adults with Cognitive Impairment: A Retrospective Cohort Study

    by Gyeon Oh, Daniela C. Moga, David W. Fardo, Jordan P. Harp, Erin L. Abner

    Background Although gabapentin has been increasingly prescribed to older adults, the relation between gabapentin initiation and longer-term neurocognitive changes is not well understood. Thus, this study aimed to examine the association of gabapentin initiation with cognitive and motor function decline in older adult participants with cognitive impairment. Methods A retrospective cohort study was conducted using the National Alzheimer’s Coordinating Center Uniform Data Set (2005–March 2023). Participants with cognitive impairment at the visit of gabapentin initiation (i.e., index visit) were included. Using the incidence density sampling method, up to nine non-users were randomly selected for each initiator. Cognitive decline over 1 year was defined as any increase in Clinical Dementia Rating global score (CDR®GLOB) or a 1-point increase in CDR® sum of boxes (CDR®SB). Functional status decline over 1 year was defined as at least a 3-point increase in the Functional Activities Questionnaire (FAQ) sum or a 0.3-point increase of mean of FAQ. Motoric decline over 1 year was defined as new clinician reports of gait disorder, falls, and slowness. To mitigate confounding and selection bias, joint stabilized inverse probability of treatment weights and censoring weights were used. Analyses compared index with index + 1 and index + 2 visits. Results For the study of cognitive and functional status decline, we included 505 initiators (mean age [SD] 78.8 [7.4]; male = 45%) and 4545 non-users (79.2 [7.6]; 50.1%). For the study of motor decline, we included 353 initiators (78.3 [7.2]; 42.8%) and 3177 non-users (78.5 [7.4]; 48.1%). Gabapentin initiation was not statistically associated with decline on CDR®GLOB, CDR®SB, FAQ sum, or mean FAQ at the index + 1 or index + 2 visits. However, gabapentin initiation was significantly associated with increased odds of new falls at the index + 2 visit (odds ratio [95% confidence interval] 2.5 [1.3, 4.6]). Conclusions Over 1 or 2 years of follow-up, gabapentin initiation was not associated with decline in cognitive or functional status but was associated with increased odds of falling among research participants with cognitive impairment.


  • Open Access

    Matching study design to prescribing intention: The prevalent new‐user design for studying abuse‐deterrent formulations of opioids

    by Bethany L. DiPrete, Gyeon Oh, Daniela C. Moga, Nabarun Dasgupta, Svetla Slavova, Emily Slade, Chris Delcher, Brian W. Pence, Shabbar I. Ranapurwala

    Purpose: In drug studies, research designs requiring no prior exposure to certain drug classes may restrict important populations. Since abuse‐deterrent formulations (ADF) of opioids are routinely prescribed after other opioids, choice of study design, identification of appropriate comparators, and addressing confounding by “indication” are important considerations in ADF post‐marketing studies.Methods: In a retrospective cohort study using claims data (2006–2018) from a North Carolina private insurer [NC claims] and Merative MarketScan [MarketScan], we identified patients (18–64 years old) initiating ADF or non‐ADF extended‐release/long‐acting (ER/LA) opioids. We compared patient characteristics and described opioid treatment history between treatment groups, classifying patients as traditional (no opioid claims during prior six‐month washout period) or prevalent new users.Results: We identified 8415 (NC claims) and 147 978 (MarketScan) ADF, and 10 114 (NC claims) and 232 028 (MarketScan) non‐ADF ER/LA opioid initiators. Most had prior opioid exposure (ranging 64%–74%), and key clinical differences included higher prevalence of recent acute or chronic pain and surgery among patients initiating ADFs compared to non‐ADF ER/LA initiators. Concurrent immediate‐release opioid prescriptions at initiation were more common in prevalent new users than traditional new users.Conclusions: Careful consideration of the study design, comparator choice, and confounding by “indication” is crucial when examining ADF opioid use‐related outcomes.


  • Open Access

    Association of gabapentin and neuropathological hallmarks in an autopsy cohort of older adults

    by Gyeon Oh, Daniela C Moga, David W. Fardo, Jordan P. Harp, Erin L Abner

    Background: Previous studies of the association between gabapentin use and neurocognitive change have shown conflicting results. We examined the association between end‐of‐life gabapentin use and neuropathological features in older adults using National Alzheimer’s Coordinating Center Uniform Data Set and Neuropathology Data Set (9/2005‐3/2022).Methods: We conducted a cross‐sectional study including participants with at least one visit within two years before autopsy and age at visit 65+ years. Gabapentin use was determined based on the two‐year window. Outcomes of interest included burden of tau (Braak stage), amyloid (Thal stage, diffuse plaques, and neuritic plaques), α‐synuclein (Lewy bodies), cerebrovascular disease (infarcts, microinfarcts, and arteriosclerosis), hippocampal sclerosis, cerebral amyloid angiopathy, TDP‐43, and atrophy (cerebral cortex and hippocampus). Collection of Thal stage, TDP‐43, and atrophy information occurred after January 2014; these outcomes were assessed in the subset with data. For each dependent neuropathological hallmark, two models were constructed (M1: adjusted for age, sex, APOE, center, and cognitive status; M2: adjusted for M1 confounders, agitation, depression, antiseizure drug, and use of opioids). To mitigate bias, joint stabilized inverse probability of treatment and censoring weights were used.Results: We included 213 gabapentin‐users (mean age[SD]: 80.9[8.7]; male 53.5%) and 4107 non‐users (82.0[8.7]; 54.7%). Gabapentin use was associated with reduced odds of Braak stage IV‐VI vs. 0‐III, moderate/frequent vs. non/sparse diffuse plaques, presence of Lewy bodies, infarct, and cerebral amyloid angiopathy in M1 and M2, and hippocampal sclerosis in M1 (Figures 1A and 1B). For the subset outcomes, 116 gabapentin‐users (mean age [SD]: 81.0 [8.6]; male 50.9%) and 1919 non‐users (81.8 [8.9]; 54.3%) were included. Gabapentin use was associated with increased odds of Thal phase 3‐5 vs. 0‐2 in M1 and M2, and amygdala TDP‐43, hippocampus TDP‐43, and cerebral cortex atrophy in M2; whereas gabapentin use was associated with decreased odds of hippocampus atrophy in M1 and M2, and amygdala TDP‐43, hippocampus TDP‐43, and cerebral cortex atrophy in M1 (Figures 1C and 1D).Conclusion: End‐of‐life gabapentin use was not significantly associated with burden of neuropathologic features and there were no clear patterns. Further studies with increased sample sizes and better measurement of gabapentin use are needed.

  • Open Access

    Matching Study Design to Prescribing Intention: The Prevalent New-User Design for Studying Abuse-Deterrent Formulations of Opioids

    by Bethany L. DiPrete, Gyeon Oh, Daniela Moga, Nabarun Dasgupta, Svetla Slavova, Emily Slade, Chris Delcher, Brian W. Pence, Shabbar Ranapurwala

    Purpose : In drug studies, research designs requiring no prior exposure to certain drug classes may restrict important populations. Since abuse-deterrent formulations (ADF) of opioids are routinely prescribed after other opioids, choice of study design, identification of appropriate comparators, and addressing confounding by “indication” are important considerations in ADF post-marketing studies. Methods : In a retrospective cohort study using claims data (2006-2018) from a North Carolina private insurer [NC claims] and Merative MarketScan [MarketScan], we identified patients (18-64 years old) initiating ADF or non-ADF extended-release/long-acting (ER/LA) opioids. We compared patient characteristics and described opioid treatment history between treatment groups, classifying patients as traditional (no opioid claims during prior six-month washout period) or prevalent new users. Results : We identified 8,415 (NC claims) and 147,978 (MarketScan) ADF, and 10,114 (NC claims) and 232,028 (MarketScan) non-ADF ER/LA opioid initiators. Most had prior opioid exposure (ranging 64-74%), and key clinical differences included higher prevalence of recent acute or chronic pain and surgery among patients initiating ADFs compared to non-ADF ER/LA initiators. Concurrent immediate-release opioid prescriptions at initiation were more common in prevalent new users than traditional new users. Conclusions : Careful consideration of the study design, comparator choice, and confounding by “indication” is crucial when examining ADF opioid use-related outcomes.

  • Open Access

    The association of gabapentin initiation and neurocognitive changes in older adults with normal cognition

    by Gyeon Oh, Daniela C. Moga, David W. Fardo, Erin L. Abner

    Background: Gabapentin is increasingly prescribed to older adults, which raises concerns about its potential to cause neurocognitive changes. Therefore, we aimed to examine the association of gabapentin use with neurocognitive changes (i.e., cognitive decline, functional status decline, and motor function change) in older adults.Methods: We conducted a retrospective cohort study using the National Alzheimer’s Coordinating Center Uniform Data Set (UDS; September 2005-March 2021 data freeze). From the eligible sample (≥age 65 years), we identified cognitively normal new-users of gabapentin and the visit they initiated gabapentin (i.e., index visit). Initiators were matched to randomly selected nonusers on year of UDS enrollment and visit number from enrollment to index. Cognitive decline was defined as any increase in the Clinical Dementia Rating global score (CDRGLOB) and as a 1-point increase in CDR sum of boxes (CDR-SB). Functional status decline was defined as a 3-point increase in the sum of the Functional Activities Questionnaire (FAQ) and as 0.3-point increase in mean FAQ. Decline in motor function was defined as new clinician reports of gait disorder, falls, and slowness. To mitigate confounding and selection bias, we used joint stabilized inverse probability of treatment weights and stabilized inverse probability of censoring weights. All analyses were conducted comparing index to index+1 and index+2 visits.Results: From the eligible UDS participants (N = 23,059), we included 480 initiators (mean age [SD]: 78.7 [6.9]; male 34.4%); 4,320 nonusers (78.3 [7.0]; 34.4%). Gabapentin initiation was significantly associated with cognitive/functional status decline: worsening CDRGLOB at index+1 visit (odds ratio [95% confidence interval]: 1.55 [1.07, 2.25]); CDR-SB at index+1 visit (1.94 [1.22, 3.09]); and mean of FAQ at index+2 visit (1.78 [1.12, 2.83]). After excluding initiators with extant motor dysfunction (n = 21), we identified 459 initiators (78.7 [6.9]; 34.0%) and 4,131 nonusers (78.2 [6.9]; 34.7%); in this sample, gabapentin initiation was associated with increased falls at the index+2 visit (2.51 [1.19, 5.31]).Conclusion: Gabapentin initiation was significantly associated with deleterious neurocognitive changes among older adults with initially normal cognition. Further studies are needed to examine the risk/benefit of prescribing gabapentin in older adults.


  • Open Access

    Gabapentin utilization among older adults with different cognitive statuses enrolled in the National Alzheimer’s Coordinating Center (2006-2019)

    by Gyeon Oh, Daniela Moga, Erin Abner

    This study aimed to examine gabapentin utilization trends among older adults with different cognitive statuses and investigate concurrent medication use of potentially inappropriate medications. Data were extracted from National Alzheimer’s Coordinating Center Uniform Data Set (2006-2019). We estimated the yearly prevalence of gabapentin use, both overall and within subgroups defined by cognitive status [normal, mild cognitive impairment, and dementia] and demographics [age and sex] for participants aged 65+. Additionally, we assessed the prevalence of concurrent use of gabapentin with opioids, combined opioids and benzodiazepine, antidepressant, and antipsychotic. Participants reported gabapentin use increased from 2006 to 2019 in both overall and every participant subgroup. About 10-30% of gabapentin users reported to concurrently use of opioids, and more than 50% gabapentin users with dementia reported to concurrently use gabapentin with antidepressants. Given increasing use among older adults, rigorous studies are needed to examine the safety of gabapentin in this population.

  • Kentucky pharmacists’ perceptions regarding provision of hormonal contraception

    by Dustin K. Miracle, Gyeon Oh, Michael Singleton, Clark D. Kebodeaux, Joseph L. Fink, Patricia R. Freeman